Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01683188
Show Display Options
Rank Status Study
1 Terminated HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: vemurafenib + HD IL-2

Indicates status has not been verified in more than two years